Alterity Therapeutics Limited · NASDAQ (us_market)
Healthcare · Biotechnology · Australia
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-11-14$3.84 RISE2026-03-27$3.16 PEAK2026-04-20$5.15 157d | -17.7% 133d | Missed | Missed | — | — | +63.0% 24d | Missed |
DROP2025-11-14$3.84 RISE2026-03-26$3.16 PEAK2026-04-20$5.15 157d | -17.7% 132d | Missed | Missed | — | — | +63.0% 25d | Missed |
DROP2025-10-15$5.01 RISE2026-02-03$3.02 PEAK2026-04-20$5.15 187d | -39.7% 111d | Missed | Missed | — | — | +70.5% 76d | Missed |
DROP2025-08-11$5.32 RISE2025-12-17$2.92 PEAK2026-03-10$3.62 211d | -45.1% 128d | Missed | Missed | — | — | +24.0% 83d | Missed |
DROP2025-07-25$6.55 RISE2025-09-30$3.76 PEAK2025-10-15$5.01 82d | -42.6% 67d | Missed | Missed | — | — | +33.2% 15d | Missed |
DROP2025-06-09$4.84 RISE2025-06-25$3.84 PEAK2025-07-25$6.55 46d | -20.7% 16d | Missed | Missed | — | — | +70.6% 30d | Missed |
DROP2025-02-03$4.99 RISE2025-04-08$2.54 PEAK2025-06-09$4.84 126d | -49.1% 64d | Missed | Missed | — | — | +90.6% 62d | Missed |
DROP2025-01-03$4.26 RISE2025-01-29$2.91 PEAK2025-02-03$4.99 31d | -31.7% 26d | Missed | Missed | — | — | +71.5% 5d | Missed |
DROP2025-01-03$4.26 RISE2025-01-28$2.91 PEAK2025-02-03$4.99 31d | -31.7% 25d | Missed | Missed | — | — | +71.5% 6d | Missed |
DROP2024-07-19$1.80 RISE2024-11-25$1.05 PEAK2025-02-03$4.99 199d | -41.7% 129d | Missed | Missed | — | — | +375.2% 70d | Missed |
DROP2024-07-17$2.13 RISE2024-11-20$1.05 PEAK2025-02-03$4.99 201d | -50.7% 126d | Missed | Missed | — | — | +375.2% 75d | Missed |
DROP2024-07-17$2.13 RISE2024-09-18$1.20 PEAK2024-12-09$2.48 145d | -43.7% 63d | Missed | Missed | — | — | +106.7% 82d | Missed |
DROP2024-04-12$2.94 RISE2024-08-05$1.20 PEAK2024-08-27$1.55 137d | -59.2% 115d | Missed | Missed | — | — | +29.2% 22d | Missed |
DROP2024-04-12$2.94 RISE2024-06-20$1.77 PEAK2024-07-17$2.13 96d | -39.8% 69d | Missed | Missed | — | — | +20.3% 27d | Missed |
DROP2023-12-04$4.20 RISE2024-03-12$1.66 PEAK2024-04-12$2.94 130d | -60.5% 99d | Missed | Missed | — | — | +77.1% 31d | Missed |
1–15 / 36 1 / 3 | |||||||
No scored news yet for a sentiment trend.
"These data continue to strengthen the evidence that ATH434 has the potential to be the first disease-modifying treatment for MSA, a rare and devastating disease with no approved therapy," said David Stamler, M.D., CEO
– Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulation that supports diagnosis and correlates with clinical severity in patients with Multiple
2026-05-02. The following slide deck was published by Alterity Therapeutics Limited in conjunction with this event.
Alterity Therapeutics Limited (ATHE) Discusses Phase II Data and Development Strategy for ATH434 in Multiple System Atrophy April 28, 2026 1:00 PM...
This second Type C Meeting builds on Alterity's recent regulatory interactions with the FDA and represents a further step towards readiness for the planned Phase 3 pivotal trial in MSA. Alterity received written feedback
- ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale -- Effects seen on both daily function and neurological examination, consistent with previously reported activity
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received
MELBOURNE, Australia and SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity, will participate in the Bell Potter Healthcare Horizons Summit taking place 12-13 March 2026 in Sorrento, Australia. At the conference, Dr. Stamler will partic
– Neurology and Movement Disorder Specialist Adds Deep Clinical and Development Expertise –MELBOURNE, Australia and SAN FRANCISCO, March 04, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that Daniel O. Claassen, M.D., M.S., was appointed Chief Medical Advisor and will begin his role in March 2026. As a tenured profes
– Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease with no approved therapies – MELBOURNE, Australia and SAN FRANCISCO, March 02, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, recognizes Multiple System Atrophy (MSA) Awareness Month this March
− Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter.Regulatory planning activities advancing toward a pivotal Phase 3 program, including preparation for FDA End-Of-Phase-2 meeting in mid-2026.Ongoing partnering and strategic discussions with pharmaceutical companies and corporate advisers
MELBOURNE, Australia and SAN FRANCISCO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to shareholders. Dear Shareholders, Our goal for 2025 was the successful completion of the Phase 2 program investigating our lead asset, ATH434, in multiple system atrophy (MSA) and to produce data that would enable u
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued a letter to
MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity, will deliver a corporate update at the Bell Potter Healthcare Conference, a virtual event showcasing Australia’s best healthcare companies. Presentation details
– Data highlights symptom stability and enhanced efficacy signals in higher dose group – – Analysis offers valuable insights to guide ongoing development and planning of Phase 3 – MELBOURNE, Australia and SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that analyses on the baseline characteristi
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ATHE | -12.90% | +19.42% | +33.77% | -8.44% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -15.87% | +25.14% | +37.21% | -21.13% |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2015-08-25 | -5.58 | — | +100.00% |
| 2013-02-26 | -8.40 | — | +100.00% |